Released Nov 4, 2026, before the open
10-Q filed Nov 4, 2026, 35 days after period end · 0001821586-26-000015
On September 30, 2026, the Company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), seeking approval of sonelokimab (SLK) for the treatment of moderate-to-severe hidradenitis suppurativa (HS) in adults and pediatric patients 12 years of age and older.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Net Income | -$79.55M | -$69.73M | -$35.39M | -$9.43M |
| EPS Diluted | -$0.93 | -$1.10 |
MoonLake Immunotherapeutics · CIK 1821586 · Engraved from SEC EDGAR
| -$0.56 |
| -$0.18 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
MoonLake submitted a Biologics License Application to the FDA on September 30, 2026, seeking approval of sonelokimab for moderate-to-severe hidradenitis suppurativa, and expects notice of acceptance within approximately 60 days.¶1
MoonLake held $498.5 million in cash, cash equivalents and short-term marketable debt securities as of September 30, 2026, and expects sufficient capital to fund operations to mid-2028.¶2¶3
Research and development expenses were $68.9 million for the three months ended September 30, 2026, compared to $50.2 million for the three months ended June 30, 2026, an increase of $18.7 million.¶3
General and administrative expenses were $11.0 million for the three months ended September 30, 2026, compared to $11.4 million for the three months ended June 30, 2026.¶3
The Hercules Capital debt facility provides up to $400 million in additional non-dilutive funds to support potential future funding needs.¶3